CAI

Business Context and Reporting Period

Company: Caris Life Sciences, Inc. (CAI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Caris is a patient-centric AI TechBio company focused on precision oncology. It utilizes comprehensive molecular profiling (Whole Exome Sequencing, Whole Transcriptome Sequencing, and Whole Genome Sequencing) combined with AI/ML algorithms to provide diagnostic solutions for therapy selection, early detection, and minimal residual disease (MRD) tracking. As of December 31, 2025, the company had sequenced over 1,000,000 cases. The company completed its Initial Public Offering (IPO) on June 20, 2025.

Key Financial Metrics

Revenue Composition: Molecular profiling services accounted for $766.7 million (94.4% of total revenue), while Pharma research and development services accounted for $45.3 million (5.6%).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue nearly doubled, driven primarily by a 119.6% increase in molecular profiling services. This was fueled by higher clinical case volumes (199,300 cases in 2025 vs. 162,850 in 2024) and an increase in Average Selling Price (ASP) due to the commercial launch of the FDA-approved MI Cancer Seek solution in January 2025.
• Profitability Improvement: The company significantly reduced its net loss from $281.9 million to $68.1 million. Operating income turned positive at $45.1 million, compared to an operating loss of $257.1 million in 2024.
• Capital Structure: The company completed its IPO in June 2025, raising net proceeds of approximately $528.5 million. All outstanding redeemable convertible preferred stock and 2025 Convertible Notes converted to common stock upon the IPO.
• Expense Management: Research and Development expenses decreased by 10.8% to $101.6 million, while General and Administrative expenses increased by 32.8% to $225.0 million, largely due to a $37.2 million increase in stock-based compensation related to IPO vesting conditions.

Guidance, Outlook, and Risks

Outlook and Strategy

• Product Launches: The company expects to launch Caris Detect, a blood-based multi-cancer early detection (MCED) assay, as a self-pay test in the first half of 2026. It is also developing Caris ChromoSeq for hematological cancers and expanding Caris Assure for MRD tracking.
• Regulatory Status: MI Cancer Seek holds FDA PMA approval. Other solutions like Caris Assure and GPSai are currently marketed as Laboratory Developed Tests (LDTs). The regulatory landscape for LDTs remains uncertain following the vacating of the FDA's LDT Final Rule in 2025.
• Reimbursement: The company relies heavily on third-party payer coverage. Medicare coverage for MI Cancer Seek is established under the NGS NCD. Future reimbursement for early detection solutions like Caris Detect is uncertain and may initially rely on cash-pay models.

Key Risks and Contingencies

• Internal Controls: The company identified a material weakness in internal control over financial reporting related to a lack of sufficient qualified accounting resources. This weakness remained unremediated as of December 31, 2025, though remediation efforts are ongoing.
• Legal Proceedings: In March 2025, the company received a Civil Investigative Demand (CID) from the DOJ regarding compliance with Medicare's "14-day rule" for date of service. The investigation is ongoing.
• Debt Obligations: The company has $400.0 million in outstanding term loan debt due in January 2028. The debt carries a variable interest rate (10.5% as of year-end) and contains restrictive covenants.
• Supplier Concentration: The company relies on Illumina as the sole supplier for NGS instruments and reagents, creating supply chain risk.

Investor Verification Checklist

• Remediation of Material Weakness: Verify the progress of remediation efforts regarding the internal control over financial reporting material weakness, as this impacts the reliability of future financial reporting.
• DOJ Investigation Outcome: Monitor the status and potential financial impact of the DOJ investigation regarding Medicare billing compliance (14-day rule).
• Caris Detect Commercialization: Assess the adoption rates and reimbursement status of the upcoming Caris Detect launch in 2026, particularly given the reliance on a self-pay model initially.
• Reimbursement Trends: Review trends in Medicare and commercial payer reimbursement rates, specifically regarding the impact of the Protecting Access to Medicare Act (PAMA) on future pricing.
• Debt Service Capacity: Evaluate the company's ability to service its $400 million variable-rate debt and meet covenants given the current interest rate environment.